Sarepta Therapeutics, Inc. financials
Key figures from Sarepta Therapeutics, Inc.'s filings with the U.S. Securities and Exchange Commission: the latest quarter against a year earlier, and the trend across recent quarters and fiscal years.
Latest quarter vs a year earlier
| Metric | Jun 2026 | Jun 2025 | Change |
|---|---|---|---|
| Revenue | $401M | $611M | -34.3% |
| Net income | -$5M | $197M | -102.5% |
| Free cash flow | $197M | $230M | -14.4% |
| Gross margin | — | 59.0% | — |
| Operating margin | 3.3% | 18.9% | -15.6 pts |
| Net margin | -1.2% | 32.2% | -33.4 pts |
Quarterly trend
Fiscal years
| Fiscal year | Revenue | Net income | Net margin | Free cash flow | EPS (diluted) |
|---|---|---|---|---|---|
| FY Dec 2025 | $2.2B | -$713M | -32.5% | -$307M | -$7.13 |
| FY Dec 2024 | $1.9B | $235M | 12.4% | -$343M | $2.34 |
| FY Dec 2023 | $1.2B | -$536M | -43.1% | -$577M | -$5.80 |
| FY Dec 2022 | $933M | -$703M | -75.4% | -$356M | -$8.03 |
| FY Dec 2021 | $702M | -$419M | -59.7% | -$482M | -$5.15 |
* Fiscal fourth quarter computed from the annual filing minus the three reported quarters. All figures from company filings with the SEC.